NCT02009956View on ClinicalTrials.gov

EXCELLA Post-Approval Study

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 26, 2014

Primary Completion Date

March 2, 2015

Study Completion Date

June 1, 2016

Conditions
Coronary Artery Disease
Interventions
DEVICE

Subjects receiving DESyne Novolimus Eluting CSS

Trial Locations (4)

11152

Jordan Hospital, Amman

15706

Santiago de Compostela University Hospital Complex, Santiago de Compostela

22110

King Abdullah University Hospital, Irbid

54292

Krankenhaus der Barmherzigen Brüder, Trier

Sponsors
All Listed Sponsors
lead

Elixir Medical Corporation

INDUSTRY

NCT02009956 - EXCELLA Post-Approval Study | Biotech Hunter | Biotech Hunter